DAY101 for pLGG Granted Rare Pediatric Disease Status
source: pixabay.com

DAY101 for pLGG Granted Rare Pediatric Disease Status

According to a July 27 news release from biopharmaceutical company Day One Biopharmaceuticals ("Day One"), the company's therapeutic option DAY101 received Rare Pediatric Disease designation within the United States. Altogether,…

Continue Reading DAY101 for pLGG Granted Rare Pediatric Disease Status

The Weather Can Change in an Hour, But a Terminal Cancer Diagnosis Changes Your Life In Minutes

The symptoms of terminal pancreatic cancer are subtle. The disease is usually not diagnosed until it has substantially progressed, leaving a dismal five-year overall survival of five to ten percent.…

Continue Reading The Weather Can Change in an Hour, But a Terminal Cancer Diagnosis Changes Your Life In Minutes
EHA2021: Longer-Term Data Presented on Yescarta for R/R Follicular Lymphoma
https://pixabay.com/photos/hospital-infusion-hand-association-834157/

EHA2021: Longer-Term Data Presented on Yescarta for R/R Follicular Lymphoma

During the European Hematology Association (EHA)'s 26th Annual Meeting, taking place virtually, biopharmaceutical company Kite (part of Gilead) shared longer-term follow-up data on Yescarta (axicabtagene ciloleucel) for patients with relapsed…

Continue Reading EHA2021: Longer-Term Data Presented on Yescarta for R/R Follicular Lymphoma